Guideline for opioid therapy and chronic noncancer pain

Chronic noncancer pain includes any painful condition that persists for at least three months and is not associated with malignant disease.[1][1] According to seven national surveys conducted between 1994 and 2008, 15%–19% of Canadian adults live with chronic noncancer pain.[2][2] Chronic

[1]  T. Gana,et al.  Extended-release tramadol (tramadol ER) in the treatment of chronic low back pain. , 2018, Journal of opioid management.

[2]  G. Guyatt,et al.  Attitudes toward the Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain: A qualitative study. , 2016, Journal of opioid management.

[3]  Thomas Agoritsas,et al.  Creating clinical practice guidelines we can trust, use, and share: a new era is imminent. , 2013, Chest.

[4]  Rebecca S. Graves,et al.  Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. , 2002 .

[5]  Roger Chou,et al.  CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. , 2016, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[6]  Trudy van der Weijden,et al.  Decision aids that really promote shared decision making: the pace quickens , 2015, BMJ : British Medical Journal.

[7]  N. Gisev,et al.  A synthesis of oral morphine equivalents (OME) for opioid utilisation studies , 2016, Pharmacoepidemiology and drug safety.

[8]  R. Chou,et al.  CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. , 2016, JAMA.

[9]  J. Schein,et al.  Extended-release tramadol in the treatment of osteoarthritis:a multicenter, randomized, double-blind, placebo-controlled clinical trial , 2006, Current medical research and opinion.

[10]  Kathleen Saunders,et al.  Automated prediction of risk for problem opioid use in a primary care setting. , 2015, The journal of pain : official journal of the American Pain Society.

[11]  R. Urman,et al.  Prescription Opioid Abuse in Chronic Pain: An Updated Review of Opioid Abuse Predictors and Strategies to Curb Opioid Abuse (Part 2). , 2017, Pain physician.

[12]  N. J. Williams,et al.  Utah Clinical Guidelines on Prescribing Opioids for Treatment of Pain , 2010, Journal of pain & palliative care pharmacotherapy.

[13]  Hans Hansen,et al.  American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2--guidance. , 2012, Pain physician.

[14]  Benedikt Fischer,et al.  Changes in and characteristics of admissions to treatment related to problematic prescription opioid use in Ontario, 2004-2009. , 2010, Drug and alcohol dependence.

[15]  J. Loeser.  Economic implications of pain management , 1999, Acta anaesthesiologica Scandinavica.

[16]  A. Mangel,et al.  Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome , 2008, Alimentary pharmacology & therapeutics.

[17]  Gerald Gartlehner,et al.  [GRADE guidelines 15: going from evidence to recommendation - determinants of a recommendation's direction and strength]. , 2014, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.

[18]  B. Fischer,et al.  Prescription Opioid Use, Harms and Interventions in Canada: A Review Update of New Developments and Findings since 2010. , 2015, Pain physician.

[19]  G. Guyatt,et al.  Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group. , 2016, Journal of clinical epidemiology.

[20]  Christopher M. Jones,et al.  Nonmedical Prescription Opioid Use and Use Disorders Among Adults Aged 18 Through 64 Years in the United States, 2003-2013. , 2015, JAMA.

[21]  J. Rehm,et al.  Effective Canadian policy to reduce harms from prescription opioids: learning from past failures , 2016, Canadian Medical Association Journal.

[22]  Michael Baron,et al.  Significant pain reduction in chronic pain patients after detoxification from high-dose opioids. , 2006, Journal of opioid management.

[23]  R. Jamison,et al.  International association for the study of pain , 1989, Pain.

[24]  Christine Laine,et al.  Trustworthy Clinical Guidelines , 2011, Annals of Internal Medicine.

[25]  R. Rauck,et al.  Results of a Double‐blind, Placebo‐controlled, Fixed‐dose Assessment of Once‐daily OROS® Hydromorphone ER in Patients with Moderate to Severe Pain Associated with Chronic Osteoarthritis , 2013, Pain practice : the official journal of World Institute of Pain.

[26]  G. Guyatt,et al.  Addressing the limitations of the CDC guideline for prescribing opioids for chronic noncancer pain , 2016, Canadian Medical Association Journal.

[27]  M. Dapoigny,et al.  Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome , 1995, Digestive Diseases and Sciences.

[28]  G. Guyatt,et al.  Specific instructions for estimating unclearly reported blinding status in randomized trials were reliable and valid. , 2012, Journal of clinical epidemiology.

[29]  M. Lynch.  The need for a Canadian pain strategy. , 2011, Pain research & management.

[30]  S. King.  Guidelines for Prescribing Opioids for Chronic Pain , 2010 .

[31]  M. Asbridge,et al.  Self-reported practices in opioid management of chronic noncancer pain: a survey of Canadian family physicians. , 2013, Pain research & management.

[32]  J. Katz,et al.  Health utilities in people with chronic pain using a population-level survey and linked health care administrative data , 2017, Pain.

[33]  Elie A Akl,et al.  GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. , 2013, Journal of clinical epidemiology.

[34]  D. Boudreau,et al.  Opioid use behaviors, mental health and pain--development of a typology of chronic pain patients. , 2009, Drug and alcohol dependence.

[35]  G. Guyatt,et al.  Going from evidence to recommendations , 2008, BMJ : British Medical Journal.

[36]  Jeffrey S. Harris,et al.  ACOEM practice guidelines: opioids for treatment of acute, subacute, chronic, and postoperative pain. , 2014, Journal of occupational and environmental medicine.

[37]  Sara Ahmed,et al.  Clinical Implications of Tapering Chronic Opioids in a Veteran Population. , 2015, Pain medicine.

[38]  Gordon H. Guyatt,et al.  Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice; Users' Guides to the Medical Literature: Essentials of Evidence-Based Clinical Practice , 2003, BMJ : British Medical Journal.

[39]  D. DeWalt,et al.  Predictors of opioid misuse in patients with chronic pain: a prospective cohort study , 2006, BMC Health Services Research.

[40]  B. Fischer,et al.  Prescription opioid related misuse, harms, diversion and interventions in Canada: a review. , 2012, Pain physician.

[41]  A. AlcántaraMontero,et al.  CDC guidelines for prescribing opioids for chronic pain , 2017 .

[42]  B. Psaty,et al.  Opioid Prescriptions for Chronic Pain and Overdose , 2010, Annals of Internal Medicine.

[43]  D. Jasinski,et al.  Long-term opioid therapy, aberrant behaviors, and substance misuse: comparison of patients treated by resident and attending physicians in a general medical clinic. , 2012, Journal of opioid management.

[44]  T. Gana,et al.  Tramadol Hydrochloride Extended-Release Once-Daily in the Treatment of Osteoarthritis of the Knee and/or Hip: A Double-Blind, Randomized, Dose-Ranging Trial , 2011, American journal of therapeutics.

[45]  J. Tranmer,et al.  The prevalence of chronic pain and pain-related interference in the Canadian population from 1994 to 2008. , 2011, Chronic diseases and injuries in Canada.

[46]  T. Gomes,et al.  Sex Differences in Dose Escalation and Overdose Death during Chronic Opioid Therapy: A Population-Based Cohort Study , 2015, PloS one.

[47]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[48]  T. Gomes,et al.  High-Dose Opioid Prescribing and Opioid-Related Hospitalization: A Population-Based Study , 2016, PloS one.